On the evening of February 26th, Baekje Shenzhou released its 2023 A-share performance report, stating that Zebtinib's global sales in 2023 have exceeded the $1 billion mark. In 2023, the company's annual performance reached a new historical high, with a total revenue of 17.423 billion yuan, an increase of 82.1% compared to the previous year. Global product revenue continued to climb to 15.504 billion yuan, an increase of 82.8% year-on-year. Among them, the two core self-developed drugs of BeiGene have made significant progress. The global sales of BTK inhibitor Baiyueze (Zebutinib) have exceeded the threshold of one billion US dollars for the first time, becoming the first "one billion US dollar molecule" in China, with annual sales reaching RMB 9.138 billion. The anti PD-1 antibody Bazean (tirelizumab) has created a "zero breakthrough" in the field of PD-1 and has been approved in the European Union and the United Kingdom. From then on, Baekje also achieved the transition from "single soldier combat" by Zebtini to today's "double hundred going to sea".